Extraintestinal Manifestations of Inflammatory Bowel Disease

被引:527
作者
Vavricka, Stephan R. [1 ,2 ]
Schoepfer, Alain [3 ]
Scharl, Michael [1 ]
Lakatos, Peter L. [4 ]
Navarini, Alexander [5 ]
Rogler, Gerhard [1 ]
机构
[1] Univ Zurich Hosp, Dept Med, Div Gastroenterol & Hepatol, CH-8091 Zurich, Switzerland
[2] Triemlispital Zurich, Div Gastroenterol & Hepatol, Dept Med, Zurich, Switzerland
[3] CHU Vaudois, Dept Med, Div Gastroenterol & Hepatol, CH-1011 Lausanne, Switzerland
[4] Semmelweis Univ, Dept Med 1, H-1085 Budapest, Hungary
[5] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
extraintestinal manifestations; inflammatory bowel disease; arthritis; uveitis; PRIMARY SCLEROSING CHOLANGITIS; PERISTOMAL PYODERMA-GANGRENOSUM; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FISTULIZING CROHNS-DISEASE; CHRONIC ERYTHEMA-NODOSUM; TNF-ALPHA THERAPY; SWEETS-SYNDROME; ULCERATIVE-COLITIS; PERIPHERAL ARTHROPATHIES; ANKYLOSING-SPONDYLITIS;
D O I
10.1097/MIB.0000000000000392
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) are frequent and may occur before or after IBD diagnosis. EIM may impact the quality of life for patients with IBD significantly requiring specific treatment depending on the affected organ(s). They most frequently affect joints, skin, or eyes, but can also less frequently involve other organs such as liver, lungs, or pancreas. Certain EIM, such as peripheral arthritis, oral aphthous ulcers, episcleritis, or erythema nodosum, are frequently associated with active intestinal inflammation and usually improve by treatment of the intestinal activity. Other EIM, such as uveitis or ankylosing spondylitis, usually occur independent of intestinal inflammatory activity. For other not so rare EIM, such as pyoderma gangrenosum and primary sclerosing cholangitis, the association with the activity of the underlying IBD is unclear. Successful therapy of EIM is essential for improving quality of life of patients with IBD. Besides other options, tumor necrosis factor antibody therapy is an important therapy for EIM in patients with IBD.
引用
收藏
页码:1982 / 1992
页数:11
相关论文
共 139 条
[1]   Ulcerative colitis and Sweet's syndrome: A case report and review of the literature [J].
Ali, Massud ;
Duerksen, Donald R. .
CANADIAN JOURNAL OF GASTROENTEROLOGY, 2008, 22 (03) :296-298
[2]   Adalimumab Treatment for Peristomal Pyoderma Gangrenosum Associated with Crohn's Disease [J].
Alkhouri, Naim ;
Hupertz, Vera ;
Mahajan, Lori .
INFLAMMATORY BOWEL DISEASES, 2009, 15 (06) :803-806
[3]   Extraintestinal manifestations of inflammatory bowel disease [J].
Ardizzone, S. ;
Puttini, P. Sarzi ;
Cassinotti, A. ;
Porro, G. Bianchi .
DIGESTIVE AND LIVER DISEASE, 2008, 40 :S253-S259
[4]   Clinical use of Infliximab in Crohn's disease: the Edinburgh experience [J].
Arnott, IDR ;
McDonald, D ;
Williams, A ;
Ghosh, S .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (10) :1639-1646
[5]   Combined therapeutic approach: Inflammatory bowel diseases and peripheral or axial arthritis [J].
Atzeni, Fabiola ;
Ardizzone, Sandro ;
Bertani, Luca ;
Antivalle, Marco ;
Batticciotto, Alberto ;
Sarzi-Puttini, Piercarlo .
WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (20) :2469-2471
[6]  
BANET DE, 1994, J RHEUMATOL, V21, P1766
[7]   Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease [J].
Batres, LA ;
Mamula, P ;
Baldassano, RN .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2002, 34 (05) :558-560
[8]  
BECUWE C, 1989, ACTA DERM-VENEREOL, V69, P444
[9]   A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions [J].
Bennett, ML ;
Jackson, JM ;
Jorizzo, JL ;
Fleischer, AB ;
White, WL ;
Callen, JP .
MEDICINE, 2000, 79 (01) :37-46
[10]  
BENTON EC, 1985, ACTA DERM-VENEREOL, V65, P77